OBJECTIVE: This prospective randomized study evaluated the efficacy and patient tolerance of dexmedetomidine compared with midazolam for sedation in postoperative patients undergoing flexible bronchoscopy. METHODS: A total of 198 postoperative patients were randomized to receive dexmedetomidine (n = 99) or midazolam (n = 99) to produce conscious sedation for bronchoscopy. Peripheral oxygen saturation, heart rate and systolic and diastolic arterial pressures were recorded before, during and after the procedure. Patient tolerance was recorded using various visual analogue scales. RESULTS: The mean lowest peripheral oxygen saturation was significantly lower in the midazolam group than in the dexmedetomidine group. Heart rate and systolic arterial pressure were both significantly higher during bronchoscopy in the midazolam group than in the dexmedetomidine group. Bronchoscopy was well tolerated in both groups; there was no betweengroup difference in patient discomfort scores or in the percentage of patients who would accept repeat bronchoscopy.
Introduction
Flexible bronchoscopy is a key procedure for the diagnosis and treatment of pulmonary disease and is commonly performed in clinical practice. It is, however, an invasive procedure and can cause cough, shortness of breath, nose and throat irritation, and phobia. Stress during bronchoscopy can cause release of catecholamines, which may lead to tachycardia, vasoconstriction and possible myocardial ischaemia in patients with impaired cardiopulmonary function. 1 Current guidelines for bronchoscopy recommend offering sedation to patients, with the aim of improving patient comfort and cooperation, and reducing complications. 2, 3 There is currently no agreement on the W Liao, G Ma, QG Su et al. Dexmedetomidine versus midazolam sedation in bronchoscopy optimum sedative for bronchoscopy. 2 − 5 Benzodiazepines combined with opioids are the most frequently used sedative agents; of these, midazolam, a γ-aminobutyric acid agonist, is the most commonly used benzodiazepine due to its short duration of action. 6 − 8 The pharmacokinetic properties of midazolam, however, include significant variability in metabolic clearance and numerous drug−drug interactions. 9, 10 Dosedependent respiratory depression, prolonged sedation and cognitive disturbances may occur, particularly in elderly patients and in those with hepatic or renal dysfunction. 11, 12 Dexmedetomidine is an α 2adrenoreceptor agonist with a unique mechanism of action: it induces sedation via receptors within the locus coeruleus, analgesia via receptors in the spinal cord and attenuation of the stress response without significant respiratory depression. 13, 14 Several studies have demonstrated the superiority of dexmedetomidine over benzodiazepines in critically ill patients. 14, 15 To date, however, there are only limited data on evaluating dexmedetomidine for bronchoscopy and no safety data comparing dexmedetomidine with benzodiazepines in this setting.
This prospective, randomized trial was undertaken to determine whether dexmedetomidine is as effective and well tolerated as midazolam in postoperative patients undergoing flexible bronchoscopy.
Patients and methods

PATIENTS
Adult postoperative patients in the Intensive Care Unit (ICU) of the Cancer Centre, Sun Yat-sen University, Guangzhou, China, who had undergone thoracic surgery and had been referred for bronchoscopy between August 2010 and July 2011 were eligible for the study.
Written informed consent was obtained from all patients or their legally authorized representatives. The study protocol was approved by the Institutional Review Board and Ethics Committee of the Cancer Centre, Sun Yat-sen University, Guangzhou, China.
EXCLUSION CRITERIA AND RANDOMIZATION
Exclusion criteria included the inability or refusal to give informed consent, bronchoscopy through an artificial airway, intolerance or allergy to the study drugs, psychological disorders, dialysis of any type, acute hepatitis or severe liver disease (Child-Pugh class C), 16 respiratory failure, unstable angina or acute myocardial infarction, left ventricular ejection fraction < 50%, heart rate < 60 beats/min, second or third degree heart block, and systolic blood pressure < 90 mmHg despite continuous infusion with two different vasopressors before the start of study drug infusion.
Following completion of preprocedural assessments, patients were randomly assigned to receive either dexmedetomidine or midazolam based on a computergenerated randomization list.
STUDY PROCEDURES
Bronchoscopy was performed transnasally by one of three ICU physicians with the patient in a semi-recumbent position. The electrocardiogram and peripheral oxygen saturation (SpO 2 ) were monitored continuously throughout the procedure. Noninvasive blood pressure measurement was performed at the beginning of sedation, the beginning of bronchoscopy, 5 min after the beginning of bronchoscopy, at the end of bronchoscopy and 30 min after bronchoscopy. Supplemental oxygen was administered at 4 l/min via nasal cannulae to all patients. If the oxygen saturation fell W Liao, G Ma, QG Su et al.
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to ≤ 90% for > 30 s, oxygen delivery was increased to 6 l/min. 17 Nasal anaesthesia was achieved by spraying 2% lidocaine into the nasopharynx and oropharynx. Then 3 ml aliquots of 2% lidocaine were sprayed onto the vocal cords and trachea using a spray-as-you-go technique. Total lidocaine doses were recorded for each patient.
Loading doses of dexmedetomidine or midazolam were titrated in order to achieve adequate conscious sedation, indicated by the onset of ptosis. In the dexmedetomidine group, a loading dose infusion of up to 1 µg/kg over 10 min could be administered at the bronchoscopist's discretion. The starting maintenance infusion dose of dexmedetomidine was 0.5 µg/kg per hour. 13 In the midazolam group, conscious sedation was achieved initially with 2 mg midazolam, followed by further 1 mg intravenous midazolam boluses during the procedure at the bronchoscopist's discretion. 11 The dose of sedative agent was titrated during the procedure to maintain a Ramsay Sedation Scale score of 3 − 4. 18 The total dose of dexmedetomidine or midazolam administered was recorded for each patient.
Haemodynamic parameters, level of sedation, duration of bronchoscopy, bronchoscopic procedures and adverse events were recorded during the procedure on a form specifically designed for the study. Adverse events were defined as hypoxaemia (oxygen saturation < 90% for > 30 s), hypotension (systolic arterial pressure < 90 mmHg or mean arterial pressure < 60 mmHg), hypertension (systolic arterial pressure > 180 mmHg or diastolic arterial pressure > 100 mmHg), tachycardia (heart rate > 100 beats/min and/or variation > 20% from baseline value), bradycardia (heart rate < 60 beats/min), need for mandible support, need for manual ventilation, need for artificial airway or invasive ventilation, need to abort bronchoscopy and death.
At the end of the procedure, the bronchoscopist recorded their perception of cough during the procedure on a 10-point visual analogue scale, where 0 represented no cough and 10 represented incessant cough. Similarly, 2 h after bronchoscopy, patients were asked to record their perception of cough related to the procedure using the same 10-point visual analogue scale. Patients were also asked to record the discomfort associated with the procedure on a 10-point visual analogue scale, where 0 represented no discomfort and 10 represented the greatest possible discomfort. Willingness to undergo repeat bronchoscopy was also documented.
STUDY ENDPOINTS
The primary study endpoint was the mean lowest SpO 2 during bronchoscopy. Secondary endpoints comprised changes in SpO 2 , heart rate and blood presure during and after bronchoscopy compared with baseline values, the patient's subjective tolerance of the procedure, and bronchoscopist-evaluated cough scores.
STATISTICAL ANALYSES
The sample size was calculated for a twosided significance α level of 0.05 and a power of 0.9 to detect a 2% difference in the mean lowest SpO 2 between the two groups. Assuming a SD of ± 4% with a 10% loss to follow-up, the minimum number of subjects required was 95 per group.
Data were presented as the mean ± SD, number and percentage of patients, or median and interquartile range. Changes in SpO 2 , heart rate and blood pressure during bronchoscopy were analysed using repeatedmeasures analysis of variance, with time as the within-subjects factor. The mean lowest SpO 2 and other continuous parameters were All statistical analyses were performed using SPSS ® software version 13.0 (SPSS Inc., Chicago, IL, USA). All tests were two-tailed and a P-value < 0.05 was considered to be statistically significant.
Results
A total of 226 patients were assessed for eligibility in the study. Of these, 28 were excluded due to refusal to participate (n = 12), having exclusion criteria (n = 8), having borderline cardiopulmonary function and, therefore, excluded at the investigator's discretion (n = 6) or withdrawal of consent (n = 2), leaving a total of 198 patients to be randomized to receive midazolam (n = 99) or dexmedetomidine (n = 99). One patient in the midazolam group was excluded from the statistical analyses because of emergency intubation. There were no statistically significant differences in the demographic or baseline characteristics between the two groups ( Table 1) .
Details of the indications for bronchoscopy and the type and duration of procedure are given in Table 2 ; there were no statistically significant differences between the groups. The mean dose of midazolam was 5.8 mg and the mean dose of dexmedetomidine was 66.2 µg.
The mean lowest SpO 2 was lower in the midazolam group than in the dexmedetomidine group (92.0 ± 4.4% versus 93.8 ± 3.9%, P < 0.01). The SpO 2 , heart rate and blood pressure (systolic and diastolic) at various time points during bronchoscopy are shown in Fig. 1 
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between the two groups. The mean SpO 2 at 5 min after the beginning of bronchoscopy (T 3 ) and at the end of bronchoscopy (T 4 ) were significantly lower in the midazolam group than in the dexmedetomidine group (95.5 ± 2.4% versus 96.6 ± 2.0% at T 3 , P < 0.01; 95.5 ± 1.6% versus 96.2 ± 1.8% at T 4 , P < 0.01; Fig.  1A ). In addition, heart rate (80.6 ± 9.5 versus 76.1 ± 9.6 beats/min at T 2 , P < 0.01; 90.5 ± 14.3 versus 84.3 ± 11.5 beats/min at T 3 , P < 0.01; 87.8 ± 11.7 versus 82.4 ± 10.0 beats/min at T 4 , P < 0.01; Fig. 1B ) and systolic arterial pressure (132.7 ± 22.2 versus 126.9 ± 16.7 mmHg at T 3 , P < 0.05; 129.2 ± 15.8 versus 124.4 ± 12.3 mmHg at T 4 , P < 0.05; Fig. 1C ) were statistically significantly higher during bronchoscopy in the midazolam group compared with the dexmedetomidine group.
There were no statistically significant differences between the two groups in patient discomfort scores or bronchoscopistevaluated cough scores, although patientevaluated cough scores were significantly higher in the dexmedetomidine group than in the midazolam group (P < 0.001; Table 3 ). There was no statistically significant difference between the groups in the dose of instilled lidocaine. The proportions of patients who would accept repeat bronchoscopy were similar in the two groups ( Table 3) .
Adverse events experienced during the study are summarized in Table 4 . Temporary hypoxaemia was a common adverse event in both groups, with no statistically significant between-group difference, and was the most frequent event in the dexmedetomidine group. Bradycardia was also a common adverse in the dexmedetomidine group, occurring significantly more frequently than in the midazolam group (P = 0.040), but no patient required treatment for this and there were no cases of haemodynamic compromise due to the bradycardia. Tachycardia was the most frequent adverse event in the midazolam group and was significantly more frequent than in the dexmedetomidine group 
Discussion
The present study showed dexmedetomidine to provide better oxygen saturation and steadier haemodynamics than midazolam for postoperative patients undergoing conscious sedation for bronchoscopy. Overall, both drugs were equally well tolerated.
For thoracic surgery patients, inappropriate airway management during anaesthesia and operation, operative injury and postoperative pain can induce airway 
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secretion retention and cause impaired productive cough. Timely and repeated airway checks and management using bronchoscopy after surgery are, therefore, of great importance. As with other patients who undergo bronchoscopy, most postoperative thoracic surgery patients find the bronchoscopy procedure intolerable and refuse a repeat procedure. Moreover, many of these patients have impaired cardiopulmonary function and are more sensitive to irritation during bronchoscopy. It is, therefore, very important to ensure the use of appropriate sedation for bronchoscopy in postoperative patients.
Oxygen desaturation is a common complication during bronchoscopy, both in the presence and absence of oxygen 
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supplementation. This may be the result of a variety of factors, including hypoventilation secondary to sedation, the application of local anaesthetic, or partial airways obstruction by the bronchoscope itself. 2,3 Several studies have compared the influence of different sedative agents and strategies on the respiratory depressive effect of sedation during bronchoscopy. Crawford et al. 19 evaluated midazolam versus propofol for bronchoscopy sedation without supplemental oxygen and reported median lowest oxygen saturation values of 86% and 83%, respectively. Stolz et al. 17 showed that, with the routine provision of supplemental oxygen during bronchoscopy, propofol did not cause a greater fall in peripheral oxygen saturation than a combination of midazolam and hydrocodone. Yoon et al. 20 reported greater respiratory depression in patients receiving a combination of propofol and alfentanil than in those receiving propofol alone. All these trials assessed medical patients or outpatients; data from evaluation of the respiratory effects of sedation during bronchoscopy in postoperative patients requiring intensive care are limited. In the present study, although the incidence of hypoxaemia did not differ between the two groups, patients in the dexmedetomidine group had a higher mean lowest oxygen saturation during bronchoscopy than those in the midazolam group. These data are consistent with previous studies showing that dexmedetomidine had no significant effect on respiratory function and could be safely used during invasive procedures in spontaneously breathing infants and adults. 21 -24 As an invasive procedure, bronchoscopy can induce hypertension, tachycardia and tachyarrhythmias. In patients with impaired cardiopulmonary function, these changes combined with oxygen desaturation may lead to an imbalance between myocardial oxygen demand and delivery, which could cause arrhythmias, myocardial ischaemia and even infarction. The highest reported incidence of ST segment changes during bronchoscopy is 21%. 25 In a randomized, double-blind, placebo-controlled study, Matot et al. 26 reported that premedication with 150 µg oral clonidine attenuated haemodynamic responses to bronchoscopy without causing excessive haemodynamic depression and sedation. As a more highly selective α 2 -adrenoreceptor agonist than clonidine, dexmedetomidine has been shown to blunt haemodynamic responses during intubation and extubation whilst the patient is conscious. 27, 28 In the present study, patients sedated with dexmedetomidine displayed fewer sympathetic responses to bronchoscopy compared with those sedated with midazolam. Fox et al. 29 concluded that adequate midazolam-alfentanil sedation could blunt the sympathetic response to bronchoscopy, and that prophylactic labetalol had no additional advantageous effects on haemodynamic stability. It should be emphasized, however, that high doses of sedation pose a risk to patients with high complication rates, especially those with impaired cardiopulmonary function. 7 In the present study, bronchoscopy was well tolerated in both groups and the percentage of patients who would accept repeat bronchoscopy was similar. Bronchoscopist-evaluated cough scores were not significantly different between the two groups, and the doses of supplemental lidocaine used for topical anaesthesia in each group were also similar. Patientevaluated cough scores, however, were significantly higher in the dexmedetomidine group. This phenomenon might be due to a less pronounced amnesic effect with 30 There are two noteworthy limitations of the present study. First, the study design was not blind. The main reason for this was that bolus dosing is the optimum method of administration for midazolam for conscious sedation, whereas dexmedetomidine must be infused slowly to avoid hypotension. 11, 13 Secondly, most patients underwent bronchoscopy because of postoperative airway secretion retention and, therefore, the duration of most procedures was relatively short. As a result, the effect of dexmedetomidine in time-consuming bronchoscopy procedures will need to be confirmed in future studies.
In conclusion, compared with midazolam, dexmedetomidine provided better oxygen saturation with the same degree of tolerability when used for conscious sedation in postoperative patients undergoing bronchoscopy.
